Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 9, 1997, Pages 2784-2791

  Meunier, P J ^a   Confavreux, E ^a   Tupinon, I ^a   Hardouin, C ^a   Delmas, P D ^a   Balena, R ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; OSTEOCALCIN; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; ORGAN SIZE; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0030921813     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.9.2784     Document Type: Article

References (41)

1. Lindsay R. 1996 The menopause and osteoporosis. Obstet Gynecol. [Suppl II]87:16S-19S.
2. McGowan JA. 1993 Osteoporosis: assessment of bone loss and remodelling. Aging Clin Exp Res. 5:81-93.
3. Compston JE, Cooper C, Kanis JA. 1995 Bone densitometry in clinical practise. BMJ. 310:1507-1510.
4. Reeve J. 1992 Future prospects for hormone replacement therapy. Br Med Bull. 48:458-468.
5. Christiansen C. 1994 The different routes of administration and the effect of hormone replacement therapy on osteoporosis. Fertil Steril. 62:152S-156S.
6. Sagraves R. 1995 Estrogen therapy tor postmenopausal symptoms and prevention of osteoporosis. J Clin Pharmacol. 35:2-10.
7. Colditz GA, Hankinson SE, Hunter DJ, et al. 1995 The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1589-1593.
8. Davidson NE. 1995 Hormone-replacement therapy - breast versus heart versus bone. N Engl J Med. 332:1638-1639.
9. Fleisch H. 1994 The use of hisphosphonates in osteoporosis. Br J Clin Pract. 48:323-326.
10. Cooper C, Fogelman I, Mellon LJ. 1991 Bisphosphonates and vertebral fracture: an epidemiological perspective. Osteoporos Int. 2:1-4.
11. Storm T, Kollerup G, Thamsborg G, Genant HK, Sorensen OH. 1996 Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol. 23:1560-1564.
12. Watts NB, Harris ST, Genant HK, et al. 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 323:73-46.
13. Harris ST, Watts NB, Jackson RD, et al. 1993 Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 95:557-567.
14. Lin JH. 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone. 18:75-85.
15. Duboeuf F, Braillon P, Chapuy MC, et al. 1991 Bone mineral density on the hip measured with dual-energy. X-ray absorptiometry in normal elderly women and in patients with hip fracture. Osteoporos Int. 1:242-249.
16. Garnero P, Shin WJ, Gineyts E, Karpf DB, Delmas P. 1994 Comparison of new biochemical markers of bone turnover in late postmenopnusal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1693-1700.
17. Bonde M, Qvist P, Fledlius C, Riis BJ, Christiansen C. 1995 Applications of enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab. 80:864-868.
18. Griffing GT, Allen SH. 1994 Estrogen replacement therapy at menopause. How benefits outweigh risks. Postgrad Med. 96:131-140.
19. Gallagher JC, Kable WT, Goldar T. 1991 Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 90:171-178.
20. Ryan PJ, Harrison R, Black GM, Fogelman I. 1992 Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol. 99:325-328.
21. Farmer R, Lewis M. 1996 Oral contraceptives and mortality from venous thromboembolism. Lancet. 348:1095.
22. Baran DT. 1994 Osteoporosis: monitoring techniques and alternate therapies. Calcitonin, fluoride, bisphosphonates, vitamin D. Obstet Gynecol Clin North Am. 21:321-335.
23. Cooper C, Kanis JA, Compston J. 1995 How to assess drug efficacy in osteoporosis. Lancet. 345:743-744.
24. Ruenitz PC. 1995 Drugs for osteoporosis prevention: mechanisms of bone maintenance. Curr Med Chem. 2:791-802.
25. Overgaard K. 1994 Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int. 55:82-86.
26. Powell JH, DeMark BR. 1985 Clinical pharmocokinetics of diphosphonates. In: Garattini S, ed. Bone resorption, metastasis and diphosphonates. Raven Press: New York; 41-49.
27. Rodan GA, Balena R. 1993 Bisphosphonates in the treatment of metabolic bone diseases. Ann Med. 25:373-378.
28. Papapoulos SE. 1995 The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J. Med. 10:315-325.
29. Kanis JA, Gertz BJ, Singer F, Ortolani S. 1995 Rationale for the use of alendronate in osteoporosis. Osteoporos Int. 5:1-13.
30. Eisman JA, Christiansen C, McClung M, et al. 1995 Alendronate prevents bone loss at the spine and hip in recently postmenopausal women. J Bone Miner Res. 10:S176-S179.
31. Herd RJM, Black GM, Ryan PJ, Fogelman I. 1995 A 152 patient double blind placebo-controlled study of cyclical etidronate for the prevention of early post-menopausal bone loss. J Bone Miner Res. 10:S57.
32. Wimalawansa SJ. 1995 Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four year randomized study. Am J Med. 99:36-42.
33. Mortensen L, Bekker P, Van De Ouweland F, et al. 1995 Prevention of early postmenopausal bone loss by risedronate: a two year study. J Bone Miner Res. [Suppl 1]10:S140 (Abstract).
34. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. 1994 Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 9:1833-1837.
35. Ravn P, Christensen J, Clemmesen B, Riis BJs, Christiansen C. 1996 The effect on bone mass and bone markers of ibandronate treatment in postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study with 1-year follow-up. Osteoporos Int. [Suppl 1]6:PTU607.
36. Vedi S, Croucher PI, Garrahan NJ, Compston JE. 1996 Effects of hormone replacement therapy on cancellous bone microstructure in postmenopausal women. Bone. 19:69-72.
37. van Staa TP, Abenhaim L, Cooper C. 1996 Bone safety of cyclical etidronate. J Bone Miner Res. 11:S343.
38. Lufkin EG, Argueta R, Whitaker MD, et al. 1994 Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int. 4:320-322.
39. de Groen PC, Lubbe DF, Hirsch LJ, et al. 1996 Esophagitis associated with the use of alendronate. N Engl J Med. 335:1016-1021.
40. Storm T, Steiniche T, Thamsborg G, Melsen F. 1993 Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 8:199-208.
41. Storm T, Sorensen HA, Thamsborg G, et al. 1996 Bone histomorphometric changes after up to seven years of cyclical etidronate treatment. J Bone Miner Res. 11:P244 (Abstract).